List of Excipients in Branded Drug ISOVUE-M 200

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
General Injectables & Vaccines Inc	ISOVUE-M 200	iopamidol	52584-411	EDETATE CALCIUM DISODIUM
General Injectables & Vaccines Inc	ISOVUE-M 200	iopamidol	52584-411	TROMETHAMINE

ISOVUE-M 200 Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

ISOVUE-M 200 is a sterile, preservative-free intrathecal iopamidol injection containing 200 mg organically bound iodine per milliliter. Its excipient system is deliberately narrow: water for injection, tromethamine for pH control, edetate calcium disodium as a chelating agent, and hydrochloric acid for pH adjustment. The principal commercial opportunities are in sterile excipient supply, container-closure systems, ready-to-use presentations, injectable manufacturing, and differentiated low-risk formulations rather than in conventional oral-drug excipient innovation.

What is ISOVUE-M 200 and who markets it?

ISOVUE-M 200 is a nonionic, water-soluble radiographic contrast medium used for intrathecal procedures, including contrast enhancement during myelography. The active ingredient is iopamidol, a triiodinated benzoic-acid derivative.

Attribute	ISOVUE-M 200
Active ingredient	Iopamidol
Iodine concentration	200 mg iodine/mL
Iopamidol concentration	Approximately 41.2% w/v
Dosage form	Sterile injectable solution
Route	Intrathecal
Preservatives	None stated in the U.S. product labeling
Manufacturer	Bracco Diagnostics Inc.
Product category	Nonionic, low-osmolar radiographic contrast agent
Primary commercial use	Myelography and other approved intrathecal radiographic procedures
FDA regulatory pathway	Approved prescription drug product under an NDA framework
Biosimilar pathway	Not applicable

The U.S. prescribing information identifies tromethamine, edetate calcium disodium, hydrochloric acid, and water for injection as formulation components or pH-adjustment materials (Bracco Diagnostics, 2023).

What excipients are used in ISOVUE-M 200?

The formulation uses excipients that address pH stability, trace-metal control, and sterile parenteral manufacturing.

Excipient	Functional role	Commercial and technical significance
Water for injection	Vehicle	Must meet compendial sterile-water requirements and control endotoxin, particulate, and microbial risk
Tromethamine	Buffering and pH control	Supports formulation pH without introducing a high ionic load
Edetate calcium disodium	Chelating agent	Binds trace metals that could catalyze degradation or affect solution stability
Hydrochloric acid	pH adjustment	Provides final pH control during manufacture
No antimicrobial preservative	Preservative-free sterile design	Appropriate for intrathecal administration and single-use presentation

The excipient system is not designed to provide taste masking, modified release, solubilization of a poorly soluble molecule, or oral absorption enhancement. The commercial value lies in maintaining a stable, clear, sterile, injectable solution with acceptable osmolality and low particulate burden.

What formulation properties constrain excipient selection?

Intrathecal administration imposes tighter formulation constraints than many intravenous products. Excipients must be evaluated for neurotoxicity, compatibility with cerebrospinal fluid, pH, osmolality, endotoxin, particulate matter, and container interaction.

pH and osmolality

The label identifies the product as a low-osmolar, nonionic contrast medium. Formulation changes that increase ionic strength or materially alter osmolality could affect tolerability and clinical use. Buffer capacity must remain sufficient to control pH during storage without creating a large salt burden.

A substitute buffer would therefore require more than routine pharmaceutical equivalence testing. The sponsor would need to demonstrate:

• Comparable pH over shelf life
• Comparable osmolality
• No increase in degradation products
• No new particulate or visible-precipitate risk
• Acceptable intrathecal safety
• Compatibility with the sterilization and filling process

Metal control

Edetate calcium disodium is commercially important because trace metals can affect oxidation pathways, discoloration, or degradation. Any change to the chelator, grade, concentration, or supplier could require a comparability assessment.

The most practical opportunity is dual sourcing of qualified edetate and tighter control of metal impurities in raw materials, water systems, manufacturing equipment, and packaging components.

Preservative-free design

A preservative-free formulation reduces the risk of neurotoxic or local tissue effects associated with antimicrobial preservatives. It also shifts the manufacturing burden to aseptic processing, terminal sterilization feasibility, container integrity, and validated single-dose handling.

A preservative-free strategy is a barrier to low-cost contract manufacturing. Facilities must support sterile filling, container-closure integrity testing, low-bioburden controls, and validated cleaning procedures.

What excipient strategy is most commercially attractive for ISOVUE-M 200?

The strongest strategy is supply-chain and manufacturing differentiation rather than a novel excipient claim.

1. Qualified excipient dual sourcing

Manufacturers can create value by qualifying multiple suppliers for tromethamine, edetate calcium disodium, hydrochloric acid, and water-system inputs. The highest-value controls include:

• Tight limits for elemental impurities
• Consistent endotoxin performance
• Low bioburden
• Lot-to-lot pH impact
• Defined particle profile
• Supplier change-control commitments
• Regional backup production

This strategy reduces interruption risk without changing the marketed formulation.

2. Injectable-grade excipient specialization

Excipient suppliers can offer prequalified materials with documented control of metals, endotoxins, extractables, and microbiological attributes. A supplier with pharmaceutical-grade documentation, validated sterilization capability, and regulatory support can command a premium over general-purpose chemical suppliers.

3. Ready-to-use presentations

Commercial opportunities include prefilled syringes, unit-dose containers, and procedure-specific packaging. These presentations could reduce preparation steps and medication-error risk in radiology departments.

The main technical issues are:

• Syringe material compatibility
• Iopamidol adsorption or extractables
• Siliconization
• Stopper and plunger compatibility
• Container-closure integrity
• Light exposure
• Sterility over shelf life
• Delivery-device dead volume

Packaging patents may offer stronger and more durable protection than excipient-composition patents if the product is redesigned for a specific delivery system.

4. Low-extractables container systems

A low-extractables vial, syringe, or polymer container can support a differentiated product profile. The relevant testing would include:

• Organic extractables
• Inorganic extractables
• Elemental impurities
• Subvisible particles
• Protein or polymer adsorption, where relevant
• Container-closure integrity
• Chemical stability under shipping conditions

For an intrathecal product, packaging changes require a conservative safety assessment because even low-level leachables may have regulatory significance.

5. Manufacturing-process control

Process IP may be more defensible than a basic excipient combination. Potentially protectable areas include:

• Addition sequence for iopamidol and excipients
• Temperature-controlled dissolution
• Metal-ion control during compounding
• pH adjustment endpoint
• Sterile filtration parameters
• Aseptic filling conditions
• Container preparation
• In-process particulate control
• Stability-indicating analytical methods

A process patent would need a meaningful technical effect, such as improved stability, lower impurity formation, reduced particulate generation, or better fill-weight consistency.

What patents protect ISOVUE-M 200?

Public product labeling identifies the formulation but does not establish an active patent estate. The core iopamidol molecule and conventional excipient combination are mature technologies. Any original composition-of-matter or early formulation protection is likely to have expired or to provide limited commercial exclusivity today.

Patent category	Likely relevance to ISOVUE-M 200	Commercial assessment
Iopamidol composition-of-matter patents	Historical	Likely expired because iopamidol is an established contrast agent
Basic aqueous formulation patents	Historical or limited	Weak protection unless claims cover a narrow stability or safety result
Excipient-combination patents	Possible but narrow	Vulnerable to design-around through concentration or buffer changes
Container-closure patents	Current opportunity	More defensible if tied to a specific syringe, stopper, or low-extractables system
Manufacturing-process patents	Current opportunity	Potentially useful if the process improves impurity, sterility, or stability control
Method-of-use patents	Limited	Potential value only for narrowly defined procedures or patient populations
Device patents	Commercially relevant	Can protect administration systems and procedure-specific packaging

A definitive patent-number and expiration-date schedule cannot be inferred from the FDA label alone. Patent protection should be assessed through current U.S. Patent and Trademark Office records, assignment data, FDA listing records, and litigation databases. The product label does not identify patent claims or exclusivity rights (U.S. Food and Drug Administration, n.d.-a; U.S. Patent and Trademark Office, n.d.).

What is the Orange Book status of ISOVUE-M 200?

The Orange Book is relevant to approved drug products, listed patents, therapeutic-equivalence evaluations, and generic approval pathways. It should not be treated as proof that every marketed contrast product has active patent protection.

For ISOVUE-M 200, the practical questions are:

1. Whether the specific strength and presentation are listed as a reference product.
2. Whether any patent information is currently listed for the product.
3. Whether an ANDA applicant can rely on the reference product’s approval.
4. Whether the proposed generic is therapeutically equivalent and pharmaceutically equivalent.
5. Whether any Paragraph IV certification would be required.

A conventional excipient change may affect pharmaceutical equivalence and labeling but does not automatically create new exclusivity. A new syringe, device, or method may be regulated through a separate combination-product or drug-device analysis, depending on the product design.

When does ISOVUE-M 200 lose exclusivity?

Iopamidol is an established active ingredient, and ISOVUE-M 200 is not a newly launched molecular entity. The principal commercial protection is therefore likely to depend on manufacturing, regulatory know-how, brand recognition, supply reliability, and product-specific patents rather than NCE exclusivity.

Exclusivity type	Relevance
New chemical entity exclusivity	Not expected for this mature active ingredient
Orphan-drug exclusivity	Not associated with the general ISOVUE-M 200 indication
Pediatric exclusivity	Must be verified in current FDA records; not assumed
Formulation exclusivity	Possible only if separately granted or supported by qualifying approval
Patent exclusivity	Depends on active, listed claims, not product age alone
Brand protection	Continues through trademark and market recognition
Regulatory know-how	Includes sterile manufacturing, stability, and filing history

The absence of NCE exclusivity does not guarantee immediate generic entry. Sterile manufacturing capacity, clinical labeling, analytical comparability, and commercial scale remain meaningful barriers.

Are Paragraph IV challenges likely for ISOVUE-M 200?

A Paragraph IV challenge would be relevant only if a generic applicant files an ANDA with a certification that an Orange Book-listed patent is invalid, unenforceable, or not infringed. For a mature contrast medium, the most likely target would be a formulation, packaging, or method patent rather than the basic active ingredient.

Potential generic strategies include:

• Matching the marketed iopamidol concentration
• Using the same or therapeutically equivalent excipient system
• Developing a different buffer system
• Using a different vial or syringe
• Challenging narrow formulation claims
• Pursuing a non-infringing manufacturing process

The primary risks for a generic applicant are not limited to patent litigation. They include sterile-filling validation, visible and subvisible particulate control, container-closure integrity, stability data, and intrathecal safety documentation.

What patent litigation and settlements affect ISOVUE-M 200?

No product-specific litigation or settlement should be assumed from the existence of the branded product. Litigation exposure would depend on current patent listings and any ANDA filing.

The likely dispute areas are:

• Whether a buffer or chelator concentration falls within a claim
• Whether a generic container infringes packaging claims
• Whether a process claim reaches the generic manufacturing method
• Whether a method-of-use claim covers the proposed label
• Whether a patent is enforceable after prosecution-history review
• Whether the patent claims are invalid for lack of novelty or obviousness

Settlement agreements could delay launch, permit an authorized generic, impose a license, or restrict use of a particular presentation. Their commercial importance would depend on the addressable market for the specific intrathecal strength.

Is there biosimilar risk for ISOVUE-M 200?

No. ISOVUE-M 200 is a small-molecule chemical drug, not a biologic. Biosimilar approval under the Public Health Service Act does not apply.

The competitive risk is generic or follow-on injectable entry through the ANDA pathway, not biosimilar substitution. Regulatory competition will focus on pharmaceutical equivalence, therapeutic equivalence, sterile manufacturing, labeling, and supply reliability.

How strong is the patent estate for ISOVUE-M 200?

The likely patent estate is moderate to weak for the legacy formulation and potentially stronger for new delivery formats or manufacturing improvements.

Asset	Relative strength	Reason
Core iopamidol molecule	Low	Mature active ingredient
Conventional excipient system	Low to moderate	Potentially easy to design around
Preservative-free sterile solution	Low alone	Broad claims may face prior-art and obviousness challenges
Low-extractables packaging	Moderate	Can be tied to measurable compatibility results
Prefilled syringe	Moderate	Device and combination claims may provide differentiation
Manufacturing process	Moderate	Stronger if linked to improved impurity or stability outcomes
Procedure-specific method	Variable	Depends on claim scope and clinical evidence
Supply and quality system	Not patent-based	Commercial barrier rather than exclusion right

What regulatory barriers affect commercial entry?

FDA approval of a follow-on intrathecal contrast product requires more than matching iodine concentration. The applicant must address:

• Active and inactive ingredient identity
• Strength and dosage form
• Sterility assurance
• Endotoxin limits
• Particulate matter
• pH and osmolality
• Stability
• Container-closure integrity
• Extractables and leachables
• In-use handling
• Labeling for intrathecal administration
• Manufacturing-site compliance

FDA guidance for parenteral products places substantial emphasis on sterile manufacturing, container systems, particulate control, and process validation (U.S. Food and Drug Administration, n.d.-b).

What commercial opportunities exist for excipient suppliers and competitors?

The addressable opportunity is specialized and operational rather than mass-market.

Highest-value opportunities

1. Pharmaceutical-grade tromethamine and edetate supply
   Suppliers can compete on impurity limits, endotoxin control, documentation, and continuity of supply.

2. Single-dose syringe systems
   A ready-to-use presentation could improve workflow in radiology and support premium pricing.

3. Low-extractables polymers and elastomers
   Packaging suppliers can differentiate through validated compatibility with concentrated iodinated solutions.

4. Sterile contract manufacturing
   Experienced aseptic fillers with capacity for small-volume parenterals are positioned to support generic or private-label entrants.

5. Analytical services
   Testing for trace metals, degradation products, particles, extractables, and container compatibility can support both lifecycle management and ANDA development.

6. Regional supply agreements
   Hospitals and group purchasing organizations may value reliable availability of intrathecal contrast products, especially where shortages or allocation risk exists.

Revenue exposure

The relevant revenue pool is limited by the specialized intrathecal indication and lower procedure volumes relative to intravenous contrast. Revenue exposure is concentrated in:

• Hospital radiology departments
• Interventional radiology
• Neurology and neurosurgery centers
• Contract purchasing organizations
• Distributor and wholesaler supply chains

A new entrant is more likely to capture share through reliable availability, competitive pricing, and packaging convenience than through a minor excipient change.

How does ISOVUE-M 200 compare with competing contrast products?

ISOVUE-M 200 competes within a specialized intrathecal segment. The key competitive variables are iodine concentration, indication, osmolality, injection volume, safety profile, supply continuity, and price.

Competitive dimension	ISOVUE-M 200 position
Active ingredient	Iopamidol
Ionization	Nonionic
Intrathecal suitability	Specifically labeled for intrathecal use
Formulation complexity	Relatively low excipient count
Differentiation potential	Packaging, supply, process, and clinical workflow
Generic substitution risk	Greater than biosimilar risk; depends on regulatory and patent barriers
Excipient innovation	Limited by intrathecal safety requirements
Manufacturing barrier	High because of sterile injectable requirements

Direct comparison with another product requires matching strength, route, labeled indication, presentation, and FDA therapeutic-equivalence status. Products that are similar in iodine concentration are not automatically interchangeable for every route or indication.

Key Takeaways

• ISOVUE-M 200 contains iopamidol at 200 mg iodine/mL in a preservative-free aqueous formulation.
• The principal excipients are tromethamine, edetate calcium disodium, hydrochloric acid, and water for injection.
• Intrathecal use sharply limits permissible excipient changes.
• The strongest commercial opportunities are dual sourcing, sterile excipient supply, low-extractables packaging, prefilled syringes, and aseptic manufacturing.
• Core molecule and conventional formulation patents are unlikely to provide durable protection for a mature product.
• Packaging and manufacturing-process patents offer better lifecycle-management potential.
• Biosimilar risk does not apply. Generic injectable competition does.
• Paragraph IV exposure depends on current Orange Book patent listings and any future ANDA filing.
• Revenue opportunity is concentrated in specialized radiology supply chains, where availability and workflow efficiency may matter more than minor formulation differentiation.

FAQs

Can edetate calcium disodium be removed from ISOVUE-M 200?

Removal would require a full formulation-development and regulatory assessment. The applicant would need to demonstrate that the change does not affect metal-catalyzed degradation, stability, particulate formation, or intrathecal safety.

Is tromethamine in ISOVUE-M 200 a patentable excipient innovation?

Tromethamine itself is not a meaningful standalone patent opportunity for this mature product. Patent value would require a specific concentration range, process, stability effect, or safety result that is not obvious from the prior art.

Could ISOVUE-M 200 be sold in a prefilled syringe?

Yes, a prefilled syringe is a plausible lifecycle-management format, but it would require container compatibility, extractables and leachables, sterility, device-function, and container-closure data.

What is the main barrier to an ISOVUE-M 200 generic?

The main barriers are sterile manufacturing, intrathecal product quality, analytical comparability, particulate and endotoxin control, and reliable supply. Patent risk may be secondary if no active formulation or device patents apply.

Can a competitor use a different buffer in an iopamidol intrathecal product?

A different buffer may be technically possible, but the competitor would need to establish comparable pH, osmolality, stability, impurity profile, sterility, and intrathecal safety. A buffer change may also affect pharmaceutical equivalence and regulatory review.

References

1. Bracco Diagnostics Inc. (2023). ISOVUE-M (iopamidol injection) prescribing information. U.S. Food and Drug Administration labeling archive.

2. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. U.S. Food and Drug Administration. (n.d.-b). Sterile drug products produced by aseptic processing: Current good manufacturing practice. FDA guidance for industry.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center and patent search resources. United States Patent and Trademark Office.

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.